Content about PITTSBURGH

April 11, 2014

Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg.

PITTSBURGH — Mylan on Friday confirmed that a federal district court has granted its request to enforce a settlement agreement between Endo Pharmaceuticals and Mylan settling patent litigation in connection with Mylan's filing of an abbreviated new drug application with the Food and Drug Administration for frovatriptan succinate tablets, 2.5 mg. This product is the generic version of Frova, which is used to treat acute migraine headaches in adults. 

March 27, 2014

PANTHERx Specialty Pharmacy on Thursday announced that it has been awarded the exclusive contract to serve as the specialty pharmacy provider for the South Carolina AIDS Drug Assistance Program Direct Dispensing service tier, effective June 1, 2014.

PITTSBURGH — PANTHERx Specialty Pharmacy on Thursday announced that it has been awarded the exclusive contract to serve as the specialty pharmacy provider for the South Carolina AIDS Drug Assistance Program Direct Dispensing service tier, effective June 1, 2014. 

As an ADAP provider, PANTHERx Specialty will help to facilitate no-cost access to essential medications for low-income, uninsured and under-insured residents of South Carolina, utilizing a combination of state and federal funds. The South Carolina ADAP serves approximately 3,200 enrollees monthly.

March 25, 2014

Mylan on Monday announced the U.S. District Court for the Northern District of West Virginia ruled in favor of upholding the validity of patents protecting Perforomist (formoterol fumarate) Inhalation Solution.

PITTSBURGH — Mylan on Monday announced the U.S. District Court for the Northern District of West Virginia ruled in favor of upholding the validity of patents protecting Perforomist (formoterol fumarate) Inhalation Solution. Mylan previously sued Teva alleging that Teva's abbreviated new drug application for this product infringed four Mylan patents covering Perforomist.  

The court's decision prevents Teva's ANDA, which has yet to receive a tentative approval from the Food and Drug Administration. 

March 19, 2014

GNC Holdings on Wednesday announced the introduction of a new line of supplement superchargers called the GNC Accelerator Series.

PITTSBURGH — GNC Holdings on Wednesday announced the introduction of a new line of supplement superchargers called the GNC Accelerator Series. Scientifically formulated by GNC experts to provide patrons with research-based performance power for all sports, training and fitness activities, GNC Accelerator Series products make it easy to personalize supplementation and benefits by adding precise doses of leucine, glutamine and creatine to any powdered supplement in a workout enthusiast's current regimen.

February 3, 2014

Mylan on Monday announced that its subsidiary has launched the world's first trastuzumab biosimilar in India, which will be marketed by Mylan as Hertraz.

MUMBAI and PITTSBURGH — Mylan on Monday announced that its subsidiary, Mylan Pharmaceuticals Private Limited, has launched the world's first trastuzumab biosimilar in India. The product — which will be marketed by Mylan as Hertraz — is used for the treatment of HER2-positive metastatic breast cancer. Hertraz is a biosimilar to Roche's Herceptin and is available in two strengths:  440mg and 150mg.

January 31, 2014

Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences' branded medicines business partner for India.

PITTSBURGH and MUMBAI, India — Mylan announced that its India-based subsidiary, Mylan Pharmaceuticals Private Limited, has been named Gilead Sciences' branded medicines business partner for India.

Under this exclusive agreement, Mylan will market and distribute in India the following drugs from Gilead:

January 28, 2014

Women who are deficient in vitamin D in the first 26 weeks of their pregnancy may be at risk of developing severe preeclampsia, a potentially life-threatening disorder diagnosed by an increase in blood pressure and protein in the urine, according to research by the University of Pittsburgh Graduate School of Public Health.

PITTSBURGH — Women who are deficient in vitamin D in the first 26 weeks of their pregnancy may be at risk of developing severe preeclampsia, a potentially life-threatening disorder diagnosed by an increase in blood pressure and protein in the urine, according to research by the University of Pittsburgh Graduate School of Public Health released last week.

January 24, 2014

Giant Eagle is making a push into Indiana with a Market District concept and GetGo, a convenience store, planned just outside of Indianapolis, according to published reports.

PITTSBURGH — Giant Eagle is making a push into Indiana with a Market District concept and GetGo, a convenience store, planned just outside of Indianapolis. 

It will be the first Giant Eagle stores in the state, which are slated to open in 2015, and additional stores in the metro area might follow.

“We are thrilled to bring our Market District and GetGo concepts to Carmel and greater Indianapolis,” Giant Eagle CEO Laura Karet said in a statement. “We are also actively evaluating opportunities for additional locations.”

 

January 23, 2014

Mylan announced that its U.S.-based subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin.

PITTSBURGH — Mylan on Thursday announced that its subsidiary has launched repaglinide tablets, a generic version of Novo Nordisk's Prandin. The drug is used to improve glycemic control in adults with Type 2 diabetes mellitus.

Repaglinide tablets in 0.5 mg, 1 mg and 2 mg had sales in the United States of approximately $212.95 million for the 12 months ending Sept. 30, 2013, according to IMS Health.

 

January 9, 2014

Mylan has launched a generic drug for preventing rejection of transplanted organs, the company said Thursday.

PITTSBURGH — Mylan has launched a generic drug for preventing rejection of transplanted organs, the company said Thursday.

The generic drug maker announced the launch of mycophenolic acid delayed-release tablets in the 180-mg and 360-mg strengths. The drug is a generic version of Novartis' Myfortic. As the first company to file a completed regulatory approval application for the generic, Mylan is entitled to 180 days in which to compete exclusively against Novartis' product before the Food and Drug Administration can approve additional generic versions.

January 8, 2014

Generic drug maker Mylan has hired a former Pfizer executive to its executive leadership team.

PITTSBURGH — Generic drug maker Mylan has hired a former Pfizer executive to its executive leadership team.

The company announced Wednesday the appointment of Adele Gulf as EVP global collaboration and strategic operations. Before working for Mylan, Gulfo served as regional president of Latin America for Pfizer's Emerging Markets Business Unit, overseeing more than 4,000 employees in 23 countries and achieving more than $3 billion in sales in Latin America in 2012.

January 7, 2014

Mylan has launched a generic version of a drug made by Pfizer for treating bladder problems, the company said Tuesday.

PITTSBURGH — Mylan has launched a generic version of a drug made by Pfizer for treating bladder problems, the company said Tuesday.

Mylan announced the launch of tolterodine tartrate extended-release capsules in the 2-mg and 4-mg strengths. The drug is used to treat overactive bladder with symptoms of urinary incontinence, urgency and frequency.

The drug is a generic version of Pfizer's Detrol LA. Tolterodine tartrate extended-release capsules had sales of about $571.5 million during the 12-month period that ended in September, according to IMS Health.

January 2, 2014

Mylan has hired Rakesh Bamzai as its president for commercial and emerging markets in India, the drug maker said.

PITTSBURGH — Mylan has hired Rakesh Bamzai as its president for commercial and emerging markets in India, the drug maker said Thursday.

Mylan said Bamzai has more than 20 years of experience in the drug industry, having previously served as president of marketing at Biocon.

December 30, 2013

Giant Eagle is expected to expand into the Indianapolis market, the Indianapolis Business Journal reported earlier this month, citing local real estate brokers.

INDIANAPOLIS — Giant Eagle is expected to expand into the Indianapolis market, the Indianapolis Business Journal reported earlier this month, citing local real estate brokers. 

December 18, 2013

Mylan has acquired rights to an experimental respiratory drug made by Pfizer, Mylan said.

PITTSBURGH — Mylan has acquired rights to an experimental respiratory drug made by Pfizer, Mylan said Wednesday.

The drug maker said it had bought exclusive worldwide development, manufacturing and commercialization rights to the drug, which was not named, but was described as a long-acting muscarinic antagonist about to enter phase-2b, or mid-stage, clinical trials. Mylan said it would develop the drug into combination therapies and that they would use a multidose dry powder inhaler technology, also licensed from Pfizer.

December 18, 2013

Four school districts have won a competition sponsored by Mylan to raise awareness about dangerous allergic reactions, the company said.

PITTSBURGH — Four school districts have won a competition sponsored by Mylan to raise awareness about dangerous allergic reactions, the company said Wednesday.

Mylan, whose Mylan Specialty division makes the EpiPen injector pen for severe allergic reactions, known as anaphylaxis, announced the winners of the Raise Your Hand for Anaphylaxis Awareness competition, for which it hired actress Julie Bowen as a celebrity spokeswoman.

December 17, 2013

Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.

PITTSBURGH — Mylan and a partnering company will be able to sell a generic version of a cancer drug starting in summer 2015, under a court settlement announced Tuesday.

Mylan said that it and Banner Pharmacaps had reached a settlement agreement with Eisai and a subsidiary of Valeant Pharmaceuticals International to resolve a lawsuit filed over their generic version of Targretin (bexarotene) capsules in the 75-mg strength. The drug is used to treat certain forms of T-cell lymphoma.

December 11, 2013

GNC on Wednesday identified the winners of the company's "Me on GNC" photo and video contest.

PITTSBURGH — GNC on Wednesday identified the winners of the company's "Me on GNC" photo and video contest. The three top winners in each category, whose stories can be seen on the ME ON GNC Contest web page, will share $100,000 in prizes. 

December 11, 2013

McKesson Pharmacy Systems and Automation introduced a new EnterpriseRx Flexible Delivery solution that expands the reach of outpatient and retail pharmacies beyond their local communities.

PITTSBURGH — McKesson Pharmacy Systems and Automation on Wednesday introduced a new EnterpriseRx Flexible Delivery solution that expands the reach of outpatient and retail pharmacies beyond their local communities. The new solution can be seen at the American Society of Health-System Pharmacists Midyear Clinical Meeting, which runs Dec. 8 to12.

December 9, 2013

Giant Eagle on Monday announced the acquisition of Rx21 Specialty Pharmacy, enabling the company to provide enhanced services to Hepatitis C and organ transplant patients and providers.

PITTSBURGH — Giant Eagle on Monday announced the acquisition of Rx21 Specialty Pharmacy, enabling the company to provide enhanced services to Hepatitis C and organ transplant patients and providers.

December 5, 2013

Giant Eagle opened its latest prototype in McMurray, Pa., on Wednesday, according to a report published in the Pittsburgh Post-Gazette.

PITTSBURGH — Giant Eagle opened its latest prototype — the Market District Express — in McMurray, Pa., on Wednesday, according to a report published in the Pittsburgh Post-Gazette

"If Giant Eagle's foodie-oriented, upscale version of its grocery stores had a fling with one of its better-dressed GetGo convenience stores, the result might be the Market District Express," the Post-Gazette observed. 

December 5, 2013

Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

PITTSBURGH — Mylan has completed its acquisition of the injectables business of Strides Arcolab, a deal worth nearly $2 billion, the drug maker said.

Mylan said the acquisition of Agila could cost up to $1.75 billion, including a $250 million contingent consideration. As part of the acquisition, Mylan will gain full commercialization rights for most of Agila's U.S. portfolio of experimental and marketed products, including cancer drugs, as well as significant product rights in Canada, Australia, Brazil, Japan and South Korea.

December 5, 2013

Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.

PITTSBURGH — Mylan has launched a generic drug for treating a condition that causes heightened levels of the protein prolactin in the blood, the company said Thursday.

Mylan announced the launch of cabergoline tablets in the 0.5-mg strength, used for treating hyperprolactinemic disorders.

Various versions of the drug had sales of about $41.67 million during the 12-month period ending in September, according to IMS Health.

 

December 2, 2013

Drug maker Mylan and the Elton John AIDS Foundation will donate $1 million to the Business Leadership Council for a Generation Born HIV Free, the two said.

PITTSBURGH — Drug maker Mylan and the Elton John AIDS Foundation will donate $1 million to the Business Leadership Council for a Generation Born HIV Free, the two said.

December 2, 2013

Vaccines have prevented an estimated 100 million cases of serious childhood contagious diseases in the nearly 90 years since the vaccine for pertussis, or whooping cough, became available, according to a new study.

PITTSBURGH — Vaccines have prevented an estimated 100 million cases of serious childhood contagious diseases in the nearly 90 years since the vaccine for pertussis, or whooping cough, became available, according to a new study.